Abstract
Priapism is an important medical condition that requires immediate evaluation, and depending on etiology, may require emergency management. Based on the classification scheme offered by a recent consensus panel, priapism can be subdivided into ischemic and nonischemic types. The nonischemic type, usually the result of perineal trauma, can be treated with conservative therapy, whereas the nonischemic type, which arises from many varied causes, mandates immediate intervention. Corporal fibrosis and permanent erectile dysfunction can result from ischemic priapism that fails to resolve with therapy.
Similar content being viewed by others
References and Recommended Reading
Berger R, Billups K, Brock G, et al.: Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res 2001, 13(Suppl 5):S39–43. State-of-the-art review of the disease. This article includes a logical, algorithmic approach to the various subtypes of priapism.
Papadopoulos I, Kelami A: Priapus and priapism. From mythology to medicine. Urology 1988, 32:385–386.
Krco MJ, Jacobs SC, Lawson RK: Priapism due to solid malignancy. Urology 1984, 23:264–266.
Wilson F, Staff WG: Malignant priapism: an unexpected response to local anaesthetic infiltration of the dorsal nerves of the penis. Br J Surg 1982, 69:469.
Chan PT, Begin LR, Arnold D, et al.: Priapism secondary to penile metastasis: a report of two cases and a review of the literature. J Surg Oncol 1998, 68:51–59.
Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ: Incidence of priapism in the general population. Urology 2001, 57:970–972. One of the few large-scale epidemiologic surveys of the incidence of priapism in the general population.
Linet OI, Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996, 334:873–877.
Fowler JE Jr, Koshy M, Strub M, Chinn SK: Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history, and sequelae. J Urol 1991, 145:65–68.
Tarry WF, Duckett JW Jr, Snyder HM 3rd: Urological complications of sickle cell disease in a pediatric population. J Urol 1987, 138:592–594.
Emond AM, Holman R, Hayes RJ, Serjeant GR: Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980, 140:1434–1437.
Mantadakis E, Cavender JD, Rogers ZR, et al.: Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999, 21:518–522.
Compton MT, Miller AH: Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry 2001, 62:362–366. An excellent review of the role of psychotropic medications in the induction of priapism.
Altman AL, Seftel AD, Brown SL, Hampel N: Cocaine associated priapism. J Urol 1999, 161:1817–1818. A review of an increasingly common cause of refractory priapism. A urine toxicology screen is now suggested for all men who present with priapism.
Steinhardt GF, Steinhardt E: Priapism in children with leukemia. Urology 1981, 18:604–606.
Suri R, Goldman JM, Catovsky D, et al.: Priapism complicating chronic granulocytic leukemia. Am J Hematol 1980, 9:295–299.
Lapan DI, Graham AR, Bangert JL, et al.: Amyloidosis presenting as priapism. Urology 1980, 15:167–170.
Maurice-Williams RS, Marsh HT: Priapism as a feature of claudication of the cauda equina. Surg Neurol 1985, 23:626–628.
Bschleipfer TH, Hauck EW, Diemer TH, et al.: Heparin-induced priapism. Int J Impot Res 2001, 13:357–359.
Zimbelman J, Lefkowitz J, Schaeffer C, et al.: Unusual complications of warfarin therapy: skin necrosis and priapism. J Pediatr 2000, 137:266–268.
Wilson SK, Klionsky BL, Rhamy RK: A new etiology of priapism: Fabry’s disease. J Urol 1973, 109:646–648.
Hebuterne X, Frere AM, Bayle J, Rampal P: Priapism in a patient treated with total parenteral nutrition. JPEN J Parenter Enteral Nutr 1992, 16:171–174.
Goulding FJ: Priapism caused by glucose phosphate isomerase deficiency. J Urol 1976, 116:819–820.
Kachhi PN, Henderson SO: Priapism after androstenedione intake for athletic performance enhancement. Ann Emerg Med 2000, 35:391–393.
Whalen RK, Whitcomb RW, Crowley WF Jr, McGovern FJ: Priapism in hypogonadal men receiving gonadotropin releasing hormone. J Urol 1991, 145:1051–1052.
Zargooshi J: Priapism as a complication of high dose testosterone therapy in a man with hypogonadism. J Urol 2000, 163:907.
Slayton W, Kedar A, Schatz D: Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 1995, 8:199–203.
Keoghane SR, Sullivan ME, Miller MA: The aetiology, pathogenesis and management of priapism. BJU Int 2002, 90:149–154.
Spycher MA, Hauri D: The ultrastructure of the erectile tissue in priapism. J Urol 1986, 135:142–147.
Broderick GA, Gordon D, Hypolite J, Levin RM: Anoxia and corporal smooth muscle dysfunction: a model for ischemic priapism. J Urol 1994, 151:259–262.
Baba H, Furusawa N, Tanaka Y, et al.: Intermittent priapism associated with lumbar spinal stenosis. Int Orthop 1994, 18:150–153.
Rubin SO: Priapism as a probable sequel to medication. Scand J Urol Nephrol 1968, 2:81–85.
Ankem MK, Ferlise VJ, Han KR, et al.: Risperidone-induced priapism. Scand J Urol Nephrol 2002, 36:91–92.
Siegel JF, Rich MA, Brock WA: Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol 1993, 150:1480–1482.
Bastuba MD, Saenz de Tejada I, Dinlenc CZ, et al.: Arterial priapism: diagnosis, treatment, and long-term followup. J Urol 1994, 151:1231–1237.
Lue TF, Hellstrom WJ, McAninch JW, Tanagho EA: Priapism: a refined approach to diagnosis and treatment. J Urol 1986, 136:104–108.
Pautler SE, Brock GB: Priapism. From Priapus to the present time. Urol Clin North Am 2001, 28:391–403. A very thorough review of all subtypes of priapism.
Seftel AD, Haas CA, Brown SL, et al.: High flow priapism complicating veno-occlusive priapism: pathophysiology of recurrent idiopathic priapism? J Urol 1998, 159:1300–1301.
Lee M, Cannon B, Sharifi R: Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol 1995, 153:1182–1183.
Futral AA, Witt MA: A closed system for corporeal irrigation in the treatment of refractory priapism. Urology 1995, 46:403–404.
Winter CC: Priapism cured by creation of fistulas between glans penis and corpora cavernosa. Trans Am Assoc Genitourin Surg 1977, 69:31–32.
Sacher EC, Sayegh E, Frensilli F, et al.: Cavernospongiosum shunt in the treatment of priapism. J Urol 1972, 108:97–100.
Sundaram CP, Fernandes ET, Ercole C, Billups KL: Management of refractory priapism with penile prostheses. Br J Urol 1997, 79:659.
Powars DR, Johnson CS: Priapism. Hematol Oncol Clin North Am 1996, 10:1363–1372.
Levine LA, Guss SP: Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol 1993, 150:475–477.
Steinberg J, Eyre RC: Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol 1995, 153:152–153.
Hakim LS, Kulaksizoglu H, Mulligan R, et al.: Evolving concepts in the diagnosis and treatment of arterial high flow priapism. J Urol 1996, 155:541–548.
Ciampalini S, Savoca G, Buttazzi L, et al.: High-flow priapism: treatment and long-term follow-up. Urology 2002, 59:110–113. A recent report on long-term follow-up of treatment of arterial priapism.
Sandock DS, Seftel AD, Herbener TE, et al.: Perineal abscess after embolization for high-flow priapism. Urology 1996, 48:308–311.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sadeghi-Nejad, H., Seftel, A.D. The etiology, diagnosis, and treatment of priapism: Review of the American Foundation for Urologic Disease Consensus Panel report. Curr Urol Rep 3, 492–498 (2002). https://doi.org/10.1007/s11934-002-0103-7
Issue Date:
DOI: https://doi.org/10.1007/s11934-002-0103-7